Westrock Healthcare at ESPACOMP 2016

Successful measurement-guided Adherence-enhancing intervention in HIV pre-exposure (PrEP)

OCT-2016 : Successful measurement-guided Adherence-enhancing intervention in HIV pre-exposure (PrEP) in low-resource settings

Oral presentation abstract 


Prophylactic use of antiretroviral drugs against infection with the human immunodeficiency virus (HIV) among individuals negative for HIV who are at high risk of being infected, is called pre-exposure prophylaxis PrEP and constitute a cornerstone for HIV eradication programs. The effectiveness of orally administered PrEP is however strikingly dependent on subjects’ adherence to the once daily dosing regimen. In this context, several projects in Sub-Saharan Africa and India have been implemented to test the feasibility, scalability and effectiveness of measurement-guided adherence-enhancing interventions in resource-limited settings.


Reliable and precise measure of medication adherence to PrEP using Medication Event Monitoring System (MEMS®) was provided in Kenya, Senegal, Nigeria, and India for HIV-prevention in high-risk populations. MEMS® records, in real-time, the date and time of each opening of a medication package as a proxy for medication ingestion. The resulting dosing history data is then used as individual feedback, at point of care, in a focused discussion between the health service providers and the subjects. The effect of this adherence-enhancing intervention is quantified and tested using longitudinal logistic regression models. 


The program is currently initiated in 4 centers located in the vicinity of Dakar, Senegal (N=161) and 5 centers in Nairobi and in remote locations by the Victoria Lake, Kenya (N=786). As of June 1st 2016, 457 subjects have baseline adherence data available. On average, 61% of the subjects take their daily medication as prescribed, with large disparities between centers ranging from 46% to 78%. Among them, 258 (56%) subjects have post-intervention adherence data highlighting an average 13% increase (p<0.001) in daily percentage of adherers.


These preliminary results are encouraging and suggest the feasibility and effectiveness of measurement-guided adherence-enhancing intervention based on MEMS<sup>®</sup> monitoring and feedback in resource-limited settings.

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,